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Abstract
Background: Talazoparib is a poly(adenosine diphosphate-ribose) polymerase inhibitor that causes death in cells with breast
cancer susceptibility gene 1 or 2 (BRCA1/2) mutations.
Methods: EMBRACA (NCT01945775) was a randomized phase III study comparing efficacy, safety, and patient-reported
outcomes (PROs) of talazoparib (1 mg) with physician’s choice of chemotherapy (PCT: capecitabine, eribulin, gemcitabine,
vinorelbine) in locally advanced or metastatic breast cancer with a germline BRCA1/2 (gBRCA1/2) mutation. Prespecified
patient subgroups were analyzed for progression-free survival, objective response, clinical benefit, duration of response, and
safety. PROs were evaluated in hormone receptor-positive (HRþ)/human epidermal growth factor receptor 2-negative
(HER2) or triple-negative breast cancer (TNBC) subgroups.
Results: Of 431 patients, 287 were randomly assigned to talazoparib and 144 to PCT. Prespecified subgroup analyses showed
prolonged progression-free survival with talazoparib (HRþ/HER2: hazard ratio¼ 0.47, 95% confidence interval¼ 0.32 to 0.71; TNBC:
hazard ratio¼ 0.60, 95% confidence interval¼ 0.41 to 0.87) and greater objective response rate (odds ratio¼ 1.97 to 11.89), clinical
benefit rate (odds ratio¼ 2.05 to 7.77), and duration of response with talazoparib in all subgroups. PROs in HRþ/HER2 and TNBC
subgroups showed consistent overall improvement and delay in time to definitive clinically meaningful deterioration with
talazoparib vs PCT. Across subgroups, common adverse events included anemia, fatigue, and nausea with talazoparib and neutro-
penia, fatigue, and nausea with PCT. Seven patients (2.4%) receiving talazoparib had grade II alopecia and 22.7% had grade I
alopecia.
Conclusions: Across all patient subgroups with gBRCA-mutated advanced breast cancer, talazoparib demonstrated clinically
significant superiority in outcomes compared with PCT.
Cancer cells with deleterious mutations in breast cancer sus-
ceptibility gene 1 or 2 (BRCA1/2) have a defective homologous
recombination DNA repair mechanism, making them highly
dependent on poly(adenosine diphosphate-ribose) polymerase
(PARP) function (1–3). In cells with a BRCA1/2 mutation, PARP
inhibition results in cell death due to a buildup of irreparably
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damaged DNA (1–3). Talazoparib, a potent PARP inhibitor, not
only blocks enzymatic activity but also traps PARP at sites of
DNA damage, a mechanism that might be more effective at
inducing cancer cell death than enzymatic inhibition alone
(4–7). Talazoparib was recently approved by the US Food and
Drug Administration, European Medicines Agency, and in other
countries (8,9).
In phase II and III clinical trials, talazoparib was shown to pro-
vide clinical benefit to patients with germline BRCA (gBRCA)-mu-
tated locally advanced or metastatic breast cancer (10,11). The
phase III EMBRACA study compared the efficacy, safety, and
patient-reported outcomes (PROs) of talazoparib with physician’s
choice of trial-specified chemotherapy (PCT: capecitabine,
eribulin, gemcitabine, or vinorelbine). Primary results in the
intent-to-treat (ITT) population showed a significantly prolonged
progression-free survival (PFS) with talazoparib vs PCT (hazard
ratio [HR] ¼ 0.54, 95% confidence interval [CI] ¼ 0.41 to 0.71) and a
manageable safety profile (12). In the PRO-evaluable population,
statistically significant delay in time to definitive clinically mean-
ingful deterioration (TTD) and statistically significant overall
improvement in multiple patient-reported cancer-related and
breast cancer-specific symptoms, functions, and global health
status/quality of life (GHS/QoL) favoring talazoparib were ob-
served, with none statistically significantly favoring PCT (13).
Efficacy endpoints were previously reported in a limited
number of patient subgroups (12). However, it is also of interest
to analyze multiple efficacy endpoints based on other patient
factors, including age, race, geographic region, Eastern
Cooperative Oncology Group performance status (ECOG PS),
measurable disease, disease-free interval (DFI) (<12 vs
12 months), bone-only disease, prior neoadjuvant or adjuvant
therapy, capecitabine, and prior hormonal therapy. This analy-
sis expanded on the preliminary analysis (12) by further evalu-
ating outcomes across multiple efficacy, safety, and PRO
endpoints and in a broad spectrum of relevant prespecified
patient subgroups (>15 additional subgroups examined).
Methods
Study Design
Detailed study information has been published previously (12,13).
Briefly, EMBRACA was an open-label, randomized,
multinational phase III study (NCT01945775) comparing the effi-
cacy, safety, and PROs of oral talazoparib (1 mg once daily) with
PCT (capecitabine, eribulin, gemcitabine, or vinorelbine) in patients
with gBRCA-mutated locally advanced or metastatic breast cancer.
Patients with human epidermal growth factor receptor 2 (HER2)-
positive breast cancer were excluded from this study. Additional
study details are provided in the Methods section of the
Supplementary Materials (available online). The data cutoff date
was September 15, 2017.
Endpoints and Study Assessments
The primary endpoint was radiographic PFS by blinded inde-
pendent central review using Response Evaluation Criteria in
Solid Tumors version 1.1. Imaging was performed every 6 weeks
during the initial part of the study (12,13). Secondary and
exploratory efficacy endpoints included overall survival, objec-
tive response, clinical benefit at 24 weeks (defined as complete
response, partial response, or stable disease for 24 weeks), and
duration of response (DOR). Secondary and exploratory
endpoints are further detailed in the Supplementary Materials
(available online).
PROs (13) were assessed as exploratory endpoints using the
European Organisation for Research and Treatment of Cancer
QoL Questionnaire-Core 30 (EORTC QLQ-C30) and breast cancer
module (QLQ-BR23) at baseline, the beginning of each treatment
cycle (every 3 weeks), and the end of treatment (see Methods in
the Supplementary Materials, available online). In this study,
PROs for breast cancer hormonal subtypes (hormone receptor-
positive [HRþ]/human epidermal growth factor receptor 2-nega-
tive [HER2] and triple-negative breast cancer [TNBC]) were
analyzed separately.
Patient Subgroups
The following prespecified patient subgroups, including differ-
ences between subgroups, were assessed: age (<50 vs
50 years), race, geographic region, ECOG PS, centrally tested
BRCA mutation type, hormone receptor status (HRþ/HER2 or
TNBC), prior history of central nervous system (CNS) metastases
(yes vs no), measurable disease (yes vs no), visceral disease (yes
vs no), DFI (<12 vs 12 months), prior neoadjuvant or adjuvant
therapy (yes vs no), prior platinum-based chemotherapy (yes vs
no), prior capecitabine (yes vs no), prior hormonal therapy (yes
vs no), and prior cytotoxic regimens for locally advanced or meta-
static breast cancer (yes vs no).
Statistical Analyses
Statistical methodology has been described previously (12,13).
The current analyses conducted in prespecified clinically relevant
subgroups characterized baseline and demographic factors as
well as efficacy (prespecified for PFS/objective response), safety,
and PRO endpoints. The definitive clinically meaningful deterio-
ration for all TTD analyses for each arm was defined as at least a
10-point change from baseline threshold with no subsequent ob-
servation less than a 10-point change from baseline (14).
Results
Patients
A total of 431 patients were included (ITT population: talazoparib,
n¼ 287; PCT, n¼ 144). Protocol-specified PCTs included
capecitabine (44%), eribulin (40%), gemcitabine (10%), and
vinorelbine (7%) (Supplementary Figure 1, available online).
Baseline characteristics were generally balanced, although more
patients in the talazoparib arm were younger than 50 years of age,
had an ECOG greater than 0, or had a DFI of less than 12 months
(Table 1), and some differences were seen among the two breast
cancer subgroups (HRþ/HER2 or TNBC; Supplementary Table 1,
available online).
Efficacy
All subgroups demonstrated superior PFS with talazoparib vs
PCT (Figure 1; HR ¼ 0.32 to 0.76 across subgroups). For the two
breast cancer subgroups, treatment effect for PFS was HR ¼ 0.47,
95% CI ¼ 0.32 to 0.71 for HRþ/HER2 and HR ¼ 0.60, 95%
CI ¼ 0.41 to 0.87 for TNBC. Patients with measurable or nonmea-
surable disease, visceral or nonvisceral disease, DFI less than 12
or  12 months, or a history of CNS metastases (yes and no) all
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benefited from talazoparib treatment compared with PCT
(Figure 1). Of the prespecified subgroups, use of prior platinum
therapy, prior capecitabine, rest of world region, bone-only
disease, race (other than white), no prior neoadjuvant or adju-
vant chemotherapy, and nonvisceral disease were the only sub-
groups in which the 95% CI upper bound exceeded 1.0.
Similarly, the objective response rate (ORR) for talazoparib
was greater across all subgroups receiving talazoparib vs PCT
(odds ratio [OR] ¼ 1.97 to 11.89; Table 2). In several of the more
difficult-to-treat subgroups, such as visceral disease and prior
Table 1. Baseline characteristics (ITT population)
Baseline characteristics
Talazoparib
(n¼ 287)
Overall PCT
(n¼ 144)
Female, % 98.6 97.9
Age, y
n 287 144
Mean (SD) 47.5 (11.6) 49.4 (12.1)
Median 45.0 50.0
Min, max 27.0, 84.0 24.0, 88.0
Age category, no. (%)
<50 y 182 (63.4) 67 (46.5)
50 to <65 y 78 (27.2) 67 (46.5)
65 y 27 (9.4) 10 (6.9)
Race, no. (%)
White 192 (66.9) 108 (75.0)
Asian 31 (10.8) 16 (11.1)
Black or African American 12 (4.2) 1 (0.7)
Other 5 (1.7) 1 (0.7)
Not reported 47 (16.4) 18 (12.5)
Ethnicity, no. (%)
Not Hispanic or Latino 210 (73.2) 111 (77.1)
Hispanic or Latino 31 (10.8) 15 (10.4)
Not reported 46 (16.0) 18 (12.5)
ECOG PS, no. (%)
0 153 (53.3) 84 (58.3)
1 127 (44.3) 57 (39.6)
2 6 (2.1) 2 (1.4)
Stage of breast cancer, no. (%)
Locally advanced* 15 (5.2) 9 (6.3)
Metastatic disease 271 (94.4) 135 (93.8)
Number of metastatic sites, no. (%)†
1 68 (23.7) 41 (28.5)
2 88 (30.7) 43 (29.9)
3 131 (45.6) 60 (41.7)
Measurable disease by investigator,
no. (%)
Measurable 219 (76.3) 114 (79.2)
Nonmeasurable disease only 68 (23.7) 30 (20.8)
History of CNS metastases, no. (%) 42 (14.6) 20 (13.9)
Sites of disease, no. (%)
Visceral disease‡ 200 (69.7) 103 (71.5)
Bone-only disease 25 (8.7) 16 (11.1)
Hormone receptor status, no. (%)
TNBC 130 (45.3) 60 (41.7)
BRCA1þ and TNBC 100 (76.9) 43 (71.7)
BRCA2þ and TNBC 30 (23.1) 17 (28.3)
HRþ 157 (54.7) 84 (58.3)
BRCA1þ and HRþ 33 (21.0) 20 (23.8)
BRCA2þ and HRþ 124 (79.0) 64 (76.2)
BRCA status by central
laboratory, no. (%)§
270 (94.1) 138 (95.8)
BRCA1þ 123 (45.6) 60 (43.5)
BRCA2þ 147 (54.4) 78 (56.5)
BRCA status by local laboratory,
no. (%)§
17 (5.9) 6 (4.2)
BRCA1þ 10 (58.8) 3 (50.0)
BRCA2þ 7 (41.2) 3 (50.0)
Tumor histology, no. (%)
Ductal 246 (85.7) 131 (91.0)
Lobular 22 (7.7) 5 (3.5)
Other/unknown 19 (6.6) 8 (5.6)
De novo breast cancer (stage IV
at initial diagnosis), no. (%)
53 (18.5) 22 (15.3)
(continued)
Table 1. (continued)
Baseline characteristics
Talazoparib
(n¼ 287)
Overall PCT
(n¼ 144)
Disease-free interval (initial diagnosis to ABC)
<12 months, no. (%) 108 (37.6) 42 (29.2)
12 months, no. (%) 178 (62.0) 102 (70.8)
Time from initial
diagnosis of breast
cancer to randomization,
median (range), y
3.9 (0–35) 5.0 (0–28)
Prior Therapies
Prior neoadjuvant/
adjuvant therapy, no. (%)
238 (82.9) 121 (84.0)
Prior HT, no. (%) 161 (56.1) 77 (53.5)
Prior HT regimens (ABC), no. 157 84
HT regimens, median (range) 1.0 (0–6) 1.0 (0–5)
1 HT regimen, no. (%) 92 (58.6) 49 (58.3)
Prior HT regimens (any
setting), median (range)
2.0 (0–6) 2.0 (0–6)
1 HT regimen 142 (90.4) 70 (83.3)
Prior cytotoxic chemotherapies
(ABC), median (range)
1.0 (0–10) 1.0 (0–3)
Prior anthracycline
therapy, no. (%)
243 (84.7) 115 (79.9)
Prior taxane therapy, no. (%) 262 (91.3) 130 (90.3)
Prior capecitabine
therapy, no. (%)
73 (25.4) 43 (29.9)
Prior eribulin therapy, no. (%) 11 (3.8) 7 (4.9)
Prior platinum therapy, no. (%) 46 (16.0) 30 (20.8)
Prior cytotoxic chemotherapy regimens for ABC, no. (%)
0 111 (38.7) 54 (37.5)
1 107 (37.3) 54 (37.5)
2 57 (19.9) 28 (19.4)
3 11 (3.8) 8 (5.6)
4 1 (0.3) 0
*Patients were considered to have locally advanced disease if the date of first
distant metastasis was missing from case report form. ABC ¼ advanced breast
cancer; BRCA1/2¼breast cancer susceptibility gene 1 or 2; CNS ¼ central nervous
system; ECOG PS ¼ Eastern Cooperative Oncology Group performance status;
ITT ¼ intent-to-treat; HRþ ¼ hormone receptor-positive; HT ¼ hormone therapy;
max ¼ maximum; min ¼ minimum; PCT ¼ physician’s choice of chemotherapy;
TNBC ¼ triple-negative breast cancer; y ¼ years.
†The number of metastatic sites was derived from target and nontarget
lesions assessed by the investigator at baseline. These included breast (only)
lesions and counting the organ once if there were more lesions in the same
location.
‡Visceral disease was defined as non-nodal target or nontarget lesions identified
as lung, liver, kidney, heart, stomach, small intestine, colon, rectum, ovary,
uterus/endometrium, pancreas, thyroid, adrenal, or spleen at baseline.
§Determined by either central or local laboratory. If central and local
laboratory results were both available, the central result was used if positive; if
both results were entered and the central result was negative, the local result
was used.
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platinum therapy, a higher ORR was observed with talazoparib
(visceral disease: talazoparib, 62.2% vs PCT, 25.5%; prior platinum
therapy: talazoparib, 50.0% vs PCT, 24.0%). For patients without
prior platinum therapy, ORR was also higher with
talazoparib than PCT (65.2% vs 28.1%) (Table 2).
Median DOR was longer across subgroups receiving
talazoparib than PCT, with more patients showing a continued
objective response at month 12 (Supplementary Table 2, avail-
able online). For example, patients with visceral disease receiv-
ing talazoparib had a DOR approximately 2 months longer than
those receiving PCT (talazoparib, 5.3 months vs PCT, 3.1 months).
Results were similar with nonvisceral disease (talazoparib,
6.2 months vs PCT, 3.2 months). Median DOR for talazoparib was
longer for patients who had not received any prior platinum
0.00 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00
≥12 months
<12 months
≥2
1
0
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
HR+/HER2-
TNBC
BRCA2
BRCA1
ECOG PS >0
ECOG PS 0
Rest of world
Europe
North America
Other
White
Age ≥50 y
Age <50 y 182 7.6 (5.8 to 8.9) 67 4.2 (2.7 to 6.7)
105 10.9 (7.8 to 15.2) 77 5.9 (5.3 to 9.7)
0.51 (0.35 to 0.75)  .0005
287 8.6 (7.2 to 9.3) 144 5.6 (4.2 to 6.7) 0.54 (0.41 to 0.71) < .0001
0.49 (0.32 to 0.75)  .0008
192 9.0 (8.1 to 12.9) 108 5.8 (4.2 to 8.6)
95 7.0 (5.6 to 8.9) 36 4.2 (1.5 to 7.1)
0.49 (0.35 to 0.68) < .0001
0.59 (0.34 to 1.00) .0486
99 9.0 (7.0 to 12.9) 57 5.8 (4.2 to 7.6) 0.46 (0.29 to 0.74) .0009
134 8.8 (7.1 to 9.8) 56 4.2 (2.8 to 10.1) 0.52 (0.33 to 0.80) .0027
54 5.6 (5.3 to 10.9) 31 5.5 (2.8 to 8.9) 0.57 (0.31 to 1.07) .0757
153 9.0 (7.1 to 12.9) 84 5.6 (4.2 to 8.7) 0.60 (0.41 to 0.87) .0058
133 8.1 (5.8 to 9.0) 59 5.5 (2.9 to 7.1) 0.44 (0.28 to 0.67) < .0001
123 6.9 (5.3 to 8.5) 60 3.5 (2.7 to 6.7) 0.60 (0.39 to 0.90) .0130
147 9.8 (8.3 to 13.0) 78 5.7 (4.6 to 8.6) 0.47 (0.32 to 0.70) .0001
130 5.8 (5.3 to 7.7) 60 2.9 (1.7 to 4.6) 0.60 (0.41 to 0.87) .0075
157 9.4 (8.8 to 13.0) 84 6.7 (5.6 to 8.7) 0.47 (0.32 to 0.71) .0002
43 5.7 (4.1 to 8.1) 20 1.6 (1.2 to 4.3) 0.32 (0.15 to 0.68) .0016
244 8.9 (7.6 to 10.3) 124 5.9 (5.4 to 8.6) 0.58 (0.43 to 0.78) .0003
219 7.2 (6.2 to 8.6) 114 5.3 (3.3 to 6.7) 0.57 (0.42 to 0.78) .0003
68 16.4 (9.8 to 24.2) 30 6.7 (5.6 to 18.0) 0.43 (0.21 to 0.90) .0207
200 7.3 (6.8 to 8.9) 103 5.3 (2.9 to 6.7) 0.51 (0.37 to 0.70) < .0001
87 10.3 (8.5 to 22.2) 41 7.1 (5.6 to 17.4) 0.59 (0.34 to 1.03) .0586
25 16.4 (8.9 to 25.6) 16 11.6 (1.4 to 17.4) 0.50 (0.14 to 1.73) .2667
262 7.9 (6.9 to 9.0) 128 5.4 (3.5 to 6.7) 0.55 (0.41 to 0.73) < .0001
46 7.0 (4.2 to 12.9) 30 2.9 (1.5 to 11.3) 0.76 (0.40 to 1.45)  .4070
241 8.8 (7.2 to 9.4) 114 5.8 (4.6 to 8.2) 0.52 (0.39 to 0.71) < .0001
73 6.9 (5.4 to 9.4) 43 5.6 (2.9 to 6.7) 0.64 (0.39 to 1.04) .0701
214 8.9 (7.3 to 10.3) 101 5.6 (3.5 to 8.7) 0.53 (0.38 to 0.74) .0001
161 9.8 (8.9 to 12.2) 77 6.7 (5.4 to 8.9) 0.44 (0.30 to 0.66) < .0001
126 5.8 (4.4 to 7.3) 67 3.5 (2.1 to 5.8) 0.59 (0.40 to 0.87) .0063
111 9.8 (8.5 to 13.3) 54 8.7 (5.5 to 18.0) 0.57 (0.34 to 0.95) .0285
107 8.1 (5.7 to 9.2) 54 4.6 (3.3 to 8.2) 0.51 (0.33 to 0.80) .0026
69 5.8 (4.4 to 8.9) 36 4.2 (1.5 to 5.7) 0.56 (0.34 to 0.95) .0288
108 5.7 (5.2 to 8.9) 42 3.5 (2.1 to 5.9) 0.56 (0.35 to 0.90) .0145
178 9.4 (7.8 to 13.3) 102 5.8 (4.6 to 8.7) 0.47 (0.33 to 0.66) < .0001
Age 
Race
Geographic region
ECOG status
BRCA status by central testing
Hormone receptor status
History of CNS metastases
Patients with measurable disease
Patients with visceral disease
Patients with bone only
Prior platinum treatment
Prior capecitabine
Prior HT
Prior cytotoxic chemotherapy regimens for ABC
Disease-free interval
All randomized patients (ITT)
PFS by subgroups No. No.
Talazoparib
(n = 287)
Median (95% CI) 
Overall PCT
(n = 144)
Median (95% CI) 
Treatment comparison
(talazoparib vs overall PCT)
Hazard ratio (95% CI) P 
No
Yes 238 8.8 (7.2 to 9.8) 121 5.8 (4.3 to 7.1) 0.53 (0.39 to 0.72) < .0001
49 7.7 (5.7 to 9.2) 23 3.5 (1.6 to 9.7) 0.69 (0.37 to 1.31) .2564
Patients received adjuvant or neo-adjuvant chemotherapy
In favor of PCTIn favor of talazoparib
Figure 1. Progression-free survival (PFS) by blinded independent central review (BICR): talazoparib vs physician’s choice of chemotherapy (PCT; subgroup analysis).
ABC ¼ advanced breast cancer; BRCA1/BRCA2¼breast cancer susceptibility gene 1 or 2; CI ¼ confidence interval; CNS ¼ central nervous system; ECOG PS ¼ Eastern
Cooperative Oncology Group performance status; HER2 ¼ human epidermal growth factor receptor 2-negative; HRþ ¼ hormone receptor-positive; HT ¼ hormone
therapy; ITT ¼ intent-to-treat; TNBC ¼ triple-negative breast cancer; y = years.
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Table 2. Investigator-assessed unconfirmed and confirmed* objective response by subgroup (ITT with measurable disease)
Objective response by subgroup Talazoparib (n¼ 219) Overall PCT (n¼ 114)
Overall objective response, No. (% [95% CI]) 137 (62.6 [55.78 to 68.99]) 31 (27.2 [19.28 to 36.33])
OR (95% CI) 4.99 (2.93 to 8.83)
Age <50 y, No. 142 49
Objective response, No. (% [95% CI]) 88 (62.0 [53.45 to 69.98]) 11 (22.4 [11.77 to 36.62])
OR (95% CI) 5.77 (2.54 to 13.67)
Age 50 to <65 y, No. 54 57
Objective response, No. (% [95% CI]) 35 (64.8 [50.62 to 77.32]) 19 (33.3 [21.40 to 47.06])
OR (95% CI) 5.82 (2.05 to 15.11)
Age 65 y, No. 23 8
Objective response, No. (% [95% CI]) 14 (60.9 [38.54 to 80.29]) 1 (12.5 [0.32 to 52.65])
OR (95% CI) NA (1.67 to NA)
Race
White, No. 143 86
Objective response, No. (% [95% CI]) 93 (65.0 [56.62 to 72.81]) 27 (31.4 [21.81 to 42.30])
OR (95% CI) 4.52 (2.41 to 8.72)
Asian, No. (% [95% CI]) 23 13
Objective response, No. (% [95% CI]) 11 (47.8 [26.82 to 69.41]) 2 (15.4 [1.92 to 45.45])
OR (95% CI) NA
Geographic region
North America,† No. 81 45
Objective response, No. (% [95% CI]) 51 (63.0 [51.51 to 73.44]) 11 (24.4 [12.88 to 39.54])
OR (95% CI) 5.54 (2.40 to 16.09)
Europe,† No. 97 45
Objective response, No. (% [95% CI]) 57 (58.8 [48.31 to 68.67]) 13 (28.9 [16.37 to 44.31])
OR (95% CI) 3.75 (1.57 to 9.87)
Rest of world,† No. 41 24
Objective response, No. (% [95% CI]) 29 (70.7 [54.46 to 83.87]) 7 (29.2 [12.62 to 51.09])
OR (95% CI) 6.70 (1.64 to 28.39)
ECOG PS ¼ 0, No. 120 64
Objective response, No. (% [95% CI]) 77 (64.2 [54.90 to 72.71]) 14 (21.9 [12.51 to 33.97])
OR (95% CI) 6.06 (3.08 to 15.07)
ECOG PS > 0, No. 98 49
Objective response, No. (% [95% CI]) 60 (61.2 [50.85 to 70.90]) 17 (34.7 [21.67 to 49.64])
OR (95% CI) 3.32 (1.47 to 7.37)
BRCA1, No. 92 50
Objective response, No. (% [95% CI]) 59 (64.1 [53.46 to 73.87]) 11 (22.0 [11.53 to 35.96])
OR (95% CI) 7.01 (2.99 to 19.54)
BRCA2, No. 114 60
Objective response, No. (% [95% CI]) 71 (62.3 [52.72 to 71.19]) 18 (30.0 [18.85 to 43.21])
OR (95% CI) 4.15 (1.90 to 8.52)
TNBC based on most recent biopsy, No. 102 48
Objective response, No. (% [95% CI]) 63 (61.8 [51.61 to 71.21]) 6 (12.5 [4.73 to 25.25])
OR (95% CI) 11.89 (4.54 to 41.37)
HRþ/HER2, No. 117 66
Objective response, No. (% [95% CI]) 74 (63.2 [53.84 to 71.97]) 25 (37.9 [26.22 to 50.66])
OR (95% CI) 2.89 (1.43 to 5.83)
History of CNS metastasis, No. 38 19
Objective response, No. (% [95% CI]) 24 (63.2 [45.99 to 78.19]) 3 (15.8 [3.38 to 39.58])
OR (95% CI) 8.95 (1.86 to 52.26)
No history of CNS metastasis, No. 181 95
Objective response, No. (% [95% CI]) 113 (62.4 [54.94 to 69.51]) 28 (29.5 [20.56 to 39.71])
OR (95% CI) 4.48 (2.53 to 8.43)
Patients with visceral disease by investigator, No. 180 98
Objective response, No. (% [95% CI]) 112 (62.2 [54.71 to 69.33]) 25 (25.5 [17.24 to 35.31])
OR (95% CI) 5.27 (2.87 to 9.74)
Patients with nonvisceral disease by investigator, No. 39 16
Objective response, No. (% [95% CI]) 25 (64.1 [47.18 to 78.80]) 6 (37.5 [15.20 to 64.57])
OR (95% CI) 2.93 (0.85 to 15.10)
Prior neoadjuvant/adjuvant therapy, No. 183 96
Objective response, No. (% [95% CI]) 119 (65.0 [57.64 to 71.91]) 25 (26.0 [17.62 to 36.00])
OR (95% CI) 6.40 (3.41 to 11.98)
(continued)
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therapy (5.4 months) than for patients who had prior platinum
therapy (4.2 months).
Talazoparib nearly doubled the clinical benefit rate (CBR)
compared with PCT in most subgroups and tripled the CBR in
TNBC patients and those with a history of CNS metastases. The
CBR was statistically significantly greater with talazoparib com-
pared with PCT in all subgroups (OR ¼ 2.05 to 7.77) except for
those subgroups in which the lower bound of the 95% CI crossed
below 1.0 (two or more prior chemotherapies, no prior neoadju-
vant or adjuvant therapy, and Asian patients) (Figure 2).
Safety
In general, the safety profile of talazoparib was similar across
subgroups and was comparable with that seen in the safety
population in the EMBRACA and ABRAZO studies (10,11).
Common adverse events (AEs) included anemia, fatigue, and
nausea with talazoparib and nausea, fatigue, and neutropenia
with PCT (10,11). Permanent discontinuations due to AEs were
infrequent (talazoparib, 5.9%; PCT, 8.7%). Although hematologic
AEs were common with talazoparib (all grade, 68.2%), only two
(0.7%) patients permanently discontinued talazoparib for
anemia, and only one (0.3%) patient discontinued each for
thrombocytopenia and neutropenia. Notably, patients discon-
tinuing talazoparib because of hematologic AEs were younger
than 50 years; no discontinuations occurred in older age groups.
For the two breast cancer subgroups, the primary toxicities for
talazoparib were hematologic, with at least a grade III anemia (HRþ/
HER2, 38.5%; TNBC, 40.0%), neutropenia (HRþ/HER2, 16.7%;
TNBC, 26.2%), and thrombocytopenia (HRþ/HER2, 12.8%; TNBC,
16.9%). Fewer HRþ/HER2 patients had all-grade neutropenia with
talazoparib (talazoparib, 31.4%; PCT, 45.9%) than TNBC patients
(talazoparib, 38.5%; PCT, 38.5%) (Table 3). Eribulin is known to cause
more neutropenia, and only 2.5% of HRþ/HER2 patients received
eribulin as a prior therapy compared with 5.4% of TNBC patients;
differences in the extent of prior eribulin might thus account for in-
cidence of neutropenia. In the HRþ/HER2 population, no patients
experienced febrile neutropenia compared with two patients in the
TNBC population. Incidence of serious AEs with talazoparib was
similar between HRþ/HER2 (30.8%) and TNBC (33.1%) patients
(Table 3). Few patients experienced an AE that resulted in perma-
nent discontinuation of talazoparib (HRþ/HER2, 5.8%; TNBC, 6.2%).
In the overall population, grade II alopecia was reported in
2.4% (n¼ 7) of patients receiving talazoparib vs 7.9% (n¼ 10) for
PCT, and grade I alopecia was reported in 22.7% (n¼ 65) of
patients receiving talazoparib vs 19.8% (n¼ 25) for PCT. Among
patients with alopecia both in the HRþ/HER2 and TNBC popu-
lations, the majority in the PCT arm were receiving eribulin
(HRþ/HER2, 19 [59.4%]; TNBC, 9 [50.0%]), which is known
to cause alopecia. In patients younger than 50 years, any grade
alopecia was experienced by approximately 21% and 26% in the
talazoparib and PCT arms, respectively. Similarly, in patients
aged 50 to 64 years, approximately 26% and 29.5% of patients
experienced alopecia in the talazoparib- and PCT-treated
groups, respectively. In patients aged greater than or equal to 65
years, 51.9% of patients had alopecia in the talazoparib arm,
whereas only 25% had alopecia in the PCT group. The higher
proportion of older patients with alopecia should be considered
with caution because other factors might be at play, and patient
numbers in this group were much smaller.
PROs
HR1/HER22Subpopulation. For patients with HRþ/HER2
disease, a statistically significant overall change from baseline
in GHS/QoL favored talazoparib over PCT (5.8, 95% CI ¼ 0.9 to
10.7, P ¼ .02 vs PCT). A statistically significant overall change
from baseline also favored talazoparib over PCT in the physical,
role, cognitive, and social functions and the fatigue, pain,
insomnia, appetite loss, and systemic therapy side effects
symptoms (Figure 3). No statistically significant overall
between-arm difference was observed for the emotional, body
image, sexual enjoyment, sexual functioning, and future per-
spective functions or the dyspnea, constipation, diarrhea,
breast, arm, and upset by hair loss symptoms. Baseline PRO
data in patients with HRþ/HER2 disease are provided in the
Results section of the Supplementary Materials (available
online).
Table 2. (continued)
Objective response by subgroup Talazoparib (n¼ 219) Overall PCT (n¼ 114)
No prior neoadjuvant/adjuvant therapy, No. 36 18
Objective response, No. (% [95% CI]) 18 (50.0 [32.92 to 67.08]) 6 (33.3 [13.34 to 59.01])
OR (95% CI) 1.97 (0.50 to 8.54)
Prior platinum therapy, No. 38 25
Objective response, No. (% [95% CI]) 19 (50.0 [33.38 to 66.62]) 6 (24.0 [9.36 to 45.13])
OR (95% CI) 3.16 (0.88 to 15.67)
No prior platinum therapy, No. 181 89
Objective response, No. (% [95% CI]) 118 (65.2 [57.77 to 72.11]) 25 (28.1 [19.07 to 38.62])
OR (95% CI) 5.36 (2.89 to 9.89)
DFI‡ <12 months, No. 90 32
Objective response, No. (% [95% CI]) 45 (50.0 [39.27 to 60.73]) 6 (18.8 [7.21 to 36.44])
OR (95% CI) 4.86 (1.85 to 19.71)
DFI‡ 12 months, No. 129 82
Objective response, No. (% [95% CI]) 92 (71.3 [62.70 to 78.93]) 25 (30.5 [20.80 to 41.64])
OR (95% CI) 6.33 (3.19 to 12.49)
*Unconfirmed objective response contains the confirmed as well as unconfirmed responses. BRCA1/BRCA2¼breast cancer susceptibility gene 1 or 2; CI ¼ confidence in-
terval; CNS ¼ central nervous system; DFI ¼ disease-free interval; ECOG PS ¼ Eastern Cooperative Oncology Group performance status; HRþ ¼ hormone receptor-posi-
tive; ITT ¼ intent-to-treat; OR ¼ odds ratio; NA ¼ not available; PCT ¼ physician’s choice of chemotherapy; TNBC ¼ triple-negative breast cancer.
†Europe (Belgium, France, Germany, Ireland, Israel, Italy, Poland, Russia, Spain, Ukraine, United Kingdom); North America (United States); Rest of world (Australia,
Brazil, Korea, Taiwan).
‡Time from initial diagnosis of breast cancer to initial diagnosis of locally advanced or metastatic breast cancer.
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Subgroup Overall No.* Odds ratio (95% CI) P
ITT population 431 4.28 (2.69 to 6.83) < .0001
Age <50 y 249 3.92 (1.99 to 7.57) < .0001
Age ≥50 y 182 4.62 (2.26 to 9.65) < .0001
Race (white) 300 3.90 (2.29 to 6.80) < .0001
Race (other) 131 6.43 (2.09 to 16.37) .0001
Race (Asian) 47 3.28 (0.53 to 18.63) .1589
Geographic region
North America 156 4.71 (2.20 to 10.57) < .0001
Europe 190 3.39 (1.56 to 7.36) .0007
Rest of world 85 5.70 (1.70 to 17.13) .0011
ECOG PS score 0 237 5.25 (2.92 to 10.43) < .0001
ECOG PS score >0 192 2.84 (1.37 to 5.76) .0020
BRCA1 183 4.45 (2.09 to 9.69) < .0001
BRCA2 225 4.28 (2.22 to 7.94) < .0001
TNBC 190 5.77 (2.76 to 13.29) < .0001
HR+/HER2– 241 3.27 (1.77 to 6.07) < .0001
History of CNS metastasis = yes 63 7.18 (1.70 to 31.91) .0018
History of CNS metastasis = no 368 3.96 (2.43 to 6.63) < .0001
Visceral disease = yes 303 4.98 (2.71 to 8.46) < .0001
Visceral disease = no 128 3.21 (1.43 to 8.23) .0022
Prior neoadjuvant/adjuvant therapy = yes 359 4.84 (2.88 to 8.18) < .0001
Prior neoadjuvant/adjuvant therapy = no 72 2.12 (0.66 to 6.27) .1621
Prior platinum therapy = yes 76 4.21 (1.26 to 16.11) .0087
Prior platinum therapy = no 355 4.21 (2.49 to 6.93) < .0001
Prior capecitabine = yes 116 3.07 (1.22 to 7.52) .0084
Prior capecitabine = no 315 4.94 (2.81 to 8.66) < .0001
Prior hormonal therapy = yes 238 3.53 (1.88 to 6.54) < .0001
Prior hormonal therapy = no 193 5.86 (2.74 to 13.14) < .0001
Prior cytotoxic chemotherapy regimens for ABC
0 165 7.77 (3.33 to 17.83) < .0001
1 161 4.61 (2.08 to 10.14) < .0001
≥2 105 2.05 (0.73 to 5.49) .1385
DFI† <12 months 150 5.36 (2.19 to 14.11) < .0001
DFI† ≥12 months 280 4.73 (2.65 to 8.63) < .0001
Figure 2. Investigator-assessed clinical benefit rate at week 24 by subgroup (intent-to-treat [ITT] population). *No. includes both treatment arms together. †Time from
initial diagnosis of breast cancer to initial diagnosis of locally advanced or metastatic breast cancer. ABC ¼ advanced breast cancer; BRCA1/BRCA2¼breast cancer
susceptibility gene 1 or 2; CI ¼ confidence interval; CNS ¼ central nervous system; DFI ¼ disease-free interval; ECOG PS ¼ Eastern Cooperative Oncology Group perfor-
mance status; HER2 ¼ human epidermal growth factor receptor 2-negative; HRþ ¼ hormone receptor-positive; PCT ¼ physician’s choice of chemotherapy; TNBC ¼
triple-negative breast cancer; y = years.
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A statistically significant delay in TTD favoring talazoparib
over PCT was observed in GHS/QoL (median ¼ 21.1 vs
12.2 months; HR ¼ 0.41, 95% CI ¼ 0.24 to 0.70, P ¼ .0007), pain
(median ¼ 21.8 vs 10.4 months; HR ¼ 0.45, 95% CI ¼ 0.25 to 0.79,
P ¼ .004), and systemic therapy side effects (median ¼ 21.1 vs
7.9 months; HR ¼ 0.26, 95% CI ¼ 0.15 to 0.46, P < .0001)
(Supplementary Figure 2, available online). Likewise, statisti-
cally significant delay in TTD favoring talazoparib was observed
in the physical, role, emotional, cognitive, and social functions
and in the fatigue, nausea/vomiting, dyspnea, insomnia, appe-
tite loss, constipation, and breast symptoms.
TNBC Subpopulation. For the TNBC population, a statistically
significant overall change from baseline in GHS/QoL favored
talazoparib over PCT (12.5, 95% CI ¼ 7.1 to 17.8, P < .0001). A
statistically significant overall change from baseline also fa-
vored talazoparib over PCT in the physical, role, social, and
body image functions and the fatigue, pain, appetite loss,
breast, and arm symptoms (Figure 4). Baseline PRO data in
patients with TNBC are provided in the Results section of the
Supplementary Materials (available online). A statistically sig-
nificant delay in TTD favoring talazoparib over PCT was ob-
served in GHS/QoL (median ¼ 24.3 vs 4.5 months; HR ¼ 0.33, 95%
CI ¼ 0.19 to 0.57, P < .0001), pain (median ¼ 22.7 vs 5.6 months;
HR ¼ 0.25, 95% CI ¼ 0.14 to 0.45, P < .0001), and systemic therapy
side effects (median ¼ 25.6 vs 10.3 months; HR ¼ 0.45, 95% CI ¼
0.24 to 0.86, P ¼ .01) (Supplementary Figure 3, available online).
Likewise, a statistically significant delay in TTD favoring talazo-
parib over PCT was observed in physical, role, emotional, cogni-
tive, social functions, and body image, and in fatigue, insomnia,
appetite loss, and arm symptoms.
Discussion
In patients with gBRCA1/2-mutated locally advanced or metastatic
breast cancer, treatment with talazoparib was statistically signifi-
cantly superior to PCT in efficacy and PROs across multiple sub-
groups. A broad spectrum of subgroups was explored, but the focus
fell for the large part on two breast cancer patient subgroups: HRþ/
HER2 and TNBC. Patients with HRþ/HER2 breast cancer or
TNBC both experienced better outcomes with talazoparib vs PCT.
Regardless of whether the mutation was gBRCA1 or gBRCA2,
talazoparib resulted in superior clinical outcomes (PFS, objective
response, DOR, and clinical benefit) vs PCT. The duration of tala-
zoparib therapy was longer, and more patients received talazo-
parib in a 12-month period. A larger number of patients
achieved clinical benefit in the BRCA2 subgroup than in the
BRCA1 subgroup. This difference in clinical benefit is consistent
with differing biology and historical differences in outcomes be-
tween patients with gBRCA1 vs gBRCA2 mutations and meta-
static breast cancer (15–17).
Table 3. AEs, all grades: TNBC and HRþ/HER2 subgroups (safety population*)
TNBC, No. (%) HRþ/HER2, No. (%)
Adverse events, all grades
Talazoparib
(n¼ 130)
Overall PCT
(n¼ 52)
Talazoparib
(n¼ 156)
Overall PCT
(n¼ 74)
Any AE 128 (98.5) 51 (98.1) 154 (98.7) 72 (97.3)
Serious† 43 (33.1) 16 (30.8) 48 (30.8) 21 (28.4)
Resulting in permanent drug discontinuation 8 (6.2) 4 (7.7) 9 (5.8) 7 (9.5)
Hematologic
Patients with 1 hematologic AE, any grade, no. (%) 95 (73.1) 24 (46.2) 99 (63.5) 39 (52.7)
Anemia‡ 73 (56.2) 11 (21.2) 78 (50.0) 12 (16.2)
Neutropenia§ 50 (38.5) 20 (38.5) 49 (31.4) 34 (45.9)
Thrombocytopeniak 40 (30.8) 5 (9.6) 37 (23.7) 4 (5.4)
Leukopenia 24 (18.5) 10 (19.2) 25 (16.0) 7 (9.5)
Lymphopenia 11 (8.5) 2 (3.8) 10 (6.4) 2 (2.7)
Nonhematologic 20%¶
Nausea 68 (52.3) 22 (42.3) Fatigue 79 (50.6) 30 (40.5)
Fatigue 65 (50.0) 24 (46.2) Nausea 71 (45.5) 37 (50.0)
Headache 43 (33.1) 13 (25.0) Headache 50 (32.1) 15 (20.3)
Alopecia 39 (30.0)# 11 (21.2) Vomiting 45 (28.8) 18 (24.3)
Decreased appetite 33 (25.4) 13 (25.0) Diarrhea 41 (26.3) 16 (21.6)
Back pain 26 (20.0) 11 (21.2) Constipation 38 (24.4) 14 (18.9)
Vomiting 26 (20.0) 11 (21.2) Back pain 34 (21.8) 9 (12.2)
Cough 26 (20.0) 6 (11.5) Alopecia 33 (21.2)# 24 (32.4)
*Safety population included patients who received talazoparib. AE grades are evaluated based on National Cancer Institute Common Terminology Criteria for Adverse
Events version 4.03. Patients with multiple AEs were counted once for each preferred term, system organ class, and overall. AEs with action taken of permanent discon-
tinuation were taken from the AE electronic case report form. AE ¼ adverse event; HER2 ¼ human epidermal growth factor receptor 2-negative; HRþ ¼ hormone re-
ceptor-positive; PCT ¼ physician’s choice of chemotherapy; TNBC ¼ triple-negative breast cancer.
†Serious defined as any AE that results in death, is considered life-threatening or medically important, results in hospitalization/prolonged hospitalization or
persistent/significant disability/incapacity or is a congenital anomaly/birth defect.
‡The category of anemia includes reports of anemia and decreased hemoglobin. No cases of acute myeloid leukemia/myelodysplastic syndrome were reported in the
talazoparib arm; one case was reported for a patient receiving capecitabine.
§The category of neutropenia includes reports of neutropenia, decreased neutrophil count, and neutropenic sepsis.
kThe category of thrombocytopenia incudes reports of thrombocytopenia and decreased platelet count.
¶All AEs in at least 20% of patients or grade III–IV AEs in at least 2.4% of patients. For these selected toxicities, no grade IV AEs were reported in either arm.
#72 patients (25.2%) overall (ie, TNBC and HRþ populations) experienced alopecia, with 65 patients (22.7%) having grade I and seven patients (2.4%) having grade II.
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Among patients with TNBC, PFS, objective response, and clin-
ical benefit were higher in those receiving talazoparib than those
receiving PCT (HR for PFS ¼ 0.60, 95% CI ¼ 0.41 to 0.87, ORR ¼
61.8% vs 12.5%, and CBR ¼ 61.5% vs 21.7%, respectively) and in-
cluded a subset of patients with a prolonged response to talazo-
parib (17% at month 12 in TNBC patients). Similar outcomes
were observed with talazoparib over PCT for patients with HRþ/
HER2 disease (HR for PFS ¼ 0.47, 95% CI ¼ 0.32 to 0.71, ORR ¼
63.2% vs 37.9%, and CBR ¼ 74.5% vs 46.4%, respectively) and also
included a subset of patients with prolonged response to talazo-
parib (28% at month 12 in HRþ/HER2 patients).
These findings suggest that talazoparib should be consid-
ered as a possible alternative to chemotherapies like eribulin,
capecitabine, gemcitabine, and vinorelbine both for TNBC and
HRþ/HER2 patients. Similarly, when considering these find-
ings while recognizing that approximately 70% of patients in
both arms had visceral disease and approximately 60% had at
least one line of prior cytotoxic chemotherapy regimens for
advanced breast cancer, the data suggest that talazoparib
provides an important treatment option in this population. The
latest ESO–ESMO ABC4 2018 guidelines support this conclusion
with the recommendation that PARP inhibitors (olaparib or
talazoparib) should be considered as “reasonable treatment
options for patients with BRCA-associated metastatic TNBC or
luminal (after progression on endocrine therapy)/metastatic
breast cancer previously treated with an anthracycline with or
without a taxane (in the adjuvant and/or metastatic setting),
since their use is associated with a PFS benefit, improvement in
QoL, and a favorable toxicity profile” (18). Direct comparison of
platinum-based chemotherapy and PARP inhibitors is war-
ranted to shed light on the optimal treatment sequence. In addi-
tion, optimal treatment sequencing for gBRCA-mutated HRþ/
HER2 breast cancer is unknown, and current guidelines sug-
gest hormonal therapy and cyclin-dependent kinase 4/6 inhibi-
tor therapy as the primary option for treatment of HRþ/HER2
disease (15), although these guidelines also recommend the use
of a PARP inhibitor for HRþ/HER2 cancers (18).
The safety profile of talazoparib in the HRþ/HER2 and
TNBC subgroups was comparable and similar to that for the ITT
population. The tolerable safety profile was complemented by
findings from PROs. Notably, across all EORTC QLQ-C30 and
QLQ-BR23 PRO scales, none of the overall change from baseline
and TTD analyses statistically significantly favored PCT over
talazoparib. These findings demonstrate that talazoparib has
A 
GHS/QoL (P = .02)
Physical functioning (P = .002)
Role functioning (P = .001)
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B
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Pain (P = .0006)
Dyspnea
Insomnia (P = .03) 
Appetite loss (P = .0004)
Constipation
Diarrhea
Systemic therapy side effects (P = .02) 
Breast symptoms
Arm symptoms
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EORTC QLQ-C30: symptom scales
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Figure 3. Patient-reported outcomes (PROs) for the HRþ/HER2 population. A) European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life
Questionnaire-Core 30 (QLQ-C30): global health status or quality of life (GHS/QoL) and functional scales; EORTC Quality of Life Questionnaire-Breast Cancer Module
(QLQ-BR23): functional scales. B) EORTC QLQ-C30: symptom scales; EORTC QLQ-BR23: symptom scales. Forest plot model of estimated difference (talazoparib and
overall PCT) in overall change from baseline (repeated measures mixed-effect model) in PRO-evaluable population (P values are shown only if significant between-arm
differences, P< .05, were observed). Nausea/vomiting symptom scale not calculated. HRþ ¼ hormone receptor-positive; HER2 ¼ human epidermal growth factor
receptor 2-negative; PCT ¼ physician’s choice chemotherapy treatment. *The sample sizes for the “sexual enjoyment” functional scale were smaller vs other
functional scales because patients were asked to respond to this question only if they responded that they were sexually active in a previous question. †The
sample sizes for the “upset by hair loss” symptom scale were smaller vs other symptom scales because patients were asked to respond to this question only if
they responded to experiencing hair loss in a previous question. PRO-evaluable population defined as all patients who completed one or more PRO question at
baseline and one or more PRO question postbaseline.
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superior efficacy and PROs over PCT both in HRþ/HER2 and
TNBC subgroups.
While chemotherapy is often the primary choice for patients
with metastatic breast cancer and visceral disease, our data in-
dicate that talazoparib has a better PFS (HR ¼ 0.51, 95% CI ¼ 0.37
to 0.70) and ORR compared with PCT (62.2% vs 25.5%, respec-
tively) with a longer DOR (5.3 vs 3.1 months, respectively). In
addition, talazoparib was efficacious regardless of prior use of
chemotherapy regimens for advanced breast cancer, disease
site, and/or measurable disease (bone only and nonvisceral
disease had HRs of 0.50 and 0.51, respectively).
Large, phase III, randomized, controlled clinical trials com-
paring platinum monotherapy with other PCT drugs in patients
with locally advanced or metastatic breast cancer and gBRCA
mutations are lacking, although a recent phase III trial (the
Triple-Negative Breast Cancer Trial) included a small subset of
patients with gBRCA mutations (n¼ 43) and concluded that plat-
inum agents were superior in terms of PFS and OR compared
with docetaxel (19). However, PRO data from platinum-based
chemotherapy trials are limited, which may be a consideration
when deciding on treatment and sequence for individual
patients.
In the ABRAZO study, a longer platinum-free interval was
associated with increased talazoparib efficacy, suggesting that
patients who progress on platinum therapy or shortly after
stopping platinum therapy may have reduced disease sensitiv-
ity to PARP inhibitors (11). Patients enrolled in EMBRACA were
permitted to have received platinum therapy in the neoadju-
vant or adjuvant setting as long as they did not relapse within
6 months from the last dose of prior platinum therapy and were
excluded if they had objective disease progression while receiving
platinum therapy for locally advanced or metastatic disease (12).
Greater improvements in clinical outcomes were seen for
patients who received talazoparib compared with those who
received PCT although the benefit was greater in patients not
treated with prior platinum therapy (20), similar to ABRAZO (11).
Even though some key baseline characteristics (eg, aged less than
50 years; ECOG PS) were associated with a better prognosis for
patients in the chemotherapy arm (both prior platinum
therapy and no prior platinum therapy groups), efficacy benefits
of talazoparib over PCT were still observed in these subgroups,
with better prognosis. The percentage of patients permanently
discontinuing treatment because of AEs was lower with
talazoparib vs PCT regardless of prior platinum therapy, although
the percentage of individual AEs reported was higher with
talazoparib (20).
This study has some limitations because not all subgroups
could be analyzed for the full range of clinical outcomes because
some were small in size and response rates were low (especially
in the PCT arm), for example, ECOG PS greater than 0 and
history of CNS metastases. Furthermore, the study population
was largely white with limited enrollment of other races.
However, the subgroups considered to be most meaningful (ie,
HRþ/HER2 vs TNBC) were fully characterized. A further
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Sexual functioning
Sexual enjoyment*
Future perspective
A
B EORTC QLQ-C30: symptom scales
Fatigue (P = .0003)
Nausea/vomiting
Pain (P < .0001)
Dyspnea
Insomnia
Appetite loss (P = .0003)
Constipation
Diarrhea
EORTC QLQ-BR23: symptom scales
Systemic therapy side effects
Breast symptoms (P = .006)
Arm symptoms (P = .01)
Upset by hair loss†
Estimate
Favors talazoparibFavors overall PCT
-50 -40 -30 -20 -10 0 10 20 30 40 50
Estimate
Favors overall PCTFavors talazoparib
-50 -40 -30 -20 -10 0 10 20 30 40 50
Figure 4. PROs for the TNBC population. A) EORTC QLQ-C30: global health status or quality of life (GHS/QoL) and functional scales; EORTC QLQ-BR23: functional scales.
B) EORTC QLQ-C30: symptom scales; EORTC QLQ-BR23: symptom scales. Forest plot model of estimated difference (talazoparib and overall PCT) in overall change from
baseline (repeated measures mixed-effect model) in PRO-evaluable population (P values are shown only if significant between-arm differences, P< .05, were observed).
*The sample sizes for the “sexual enjoyment” functional scale were smaller vs other functional scales because patients were asked to respond to this question only if they
responded that they were sexually active in a previous question. EORTC¼ European Organisation for Research and Treatment of Cancer; HRþ ¼ hormone receptor-positive;
HER2 ¼ human epidermal growth factor receptor 2-negative; PCT ¼ physician’s choice of chemotherapy treatment; PRO ¼ patient-reported outcomes; QLQ-BR23¼Quality
of Life Questionnaire-Breast Cancer Module; QLQ-C30¼Quality of Life Questionnaire-Core 30. †The sample sizes for the “upset by hair loss” symptom scale were smaller vs
other symptom scales because patients were asked to respond to this question only if they responded to experiencing hair loss in a previous question. PRO-evaluable popu-
lation defined as all patients who completed one or more PRO question at baseline and one or more PRO question postbaseline.
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limitation of this study was the omission of platinum-based
chemotherapy as an option in the PCT arm, mainly because
single-agent, non platinum–based chemotherapy was a global
standard of care (18) for this population when the study was ini-
tially designed in 2013 and doublets or triplets (with or without
platinum therapy) were not considered appropriate for this pa-
tient population at the time. A head-to-head comparison of a
PARP inhibitor to platinum-based chemotherapy is needed to
understand the relative efficacy, toxicity, and effect on PROs.
Finally, subgroup analyses can result in false-positive results,
and therefore CIs were included in the manuscript so the reader
could better evaluate the effects in the different subgroups.
In conclusion, our data highlight that patients with gBRCA1/2-
mutated locally advanced or metastatic breast cancer across
most subgroups showed statistically significantly greater PFS,
ORR, and CBR with talazoparib vs PCT. This includes many pre-
specified subgroups (eg, HRþ/HER2 or TNBC; BRCA1 or BRCA2;
history or no history of CNS metastases; poor or good ECOG PS;
younger or older age; measurable disease or nonmeasurable dis-
ease; visceral or nonvisceral disease), although sample sizes for
some of these subgroups were small. Statistically significant
overall improvement and statistically significant delay in TTD in
PROs favored talazoparib vs PCT both in the HRþ/HER2 and
TNBC subgroups. The findings from this subgroup analysis are
consistent with those for the overall population. Analysis of these
additional prespecified subgroups will further aid clinicians in
making informed decisions regarding their treatment options for
a variety of patients with gBRCA-mutated advanced breast
cancer.
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